DP Alpha 3: Unlocking The Immune System's Potential To Fight Cancer

Target Name: HLA-DPA3

NCBI ID: G267013

HLA-DPA3

Other Name(s): major histocompatibility complex, class II, DP alpha 3 (pseudogene) | dJ1033B10.14 | Major histocompatibility complex, class II, DP alpha 3 (pseudogene)

DP Alpha 3: Unlocking The Immune System's Potential To Fight Cancer

The major histocompatibility complex (MHC) is a critical immune system protein that plays a crucial role in the immune response. The MHC class II molecules are expressed on the surface of immune cells, including T cells, B cells, and natural killer cells. Their main functions It is to present antigen peptides to CD4+ T cells and activate the cellular immune response in T cells. However, MHC molecules are also involved in regulating other immune cell functions, such as natural killer cells (NK cells) and macrophages.

HLA-DP alpha 3 is a gene that exists on the human chromosome. The protein it encodes is DP alpha 3, which belongs to MHC class II molecules. DP alpha 3 is expressed on the surface of immune cells and is mainly distributed in immune cells such as T cells, B cells, and macrophages. Research shows that DP alpha 3 plays an important role in immune cell function, such as participating in immune cell activation, proliferation and differentiation, and regulating immune cell response to antigens.

The loss of DP alpha 3 can lead to immune cell dysfunction and cause many immune-related diseases. For example, in autoimmune diseases, the loss of DP alpha 3 can lead to reduced T cell function and increase the patient's risk of disease. Furthermore, in tumor cells, the expression level of DP alpha 3 correlates with tumor growth and invasion capabilities. Therefore, studying the role of DP alpha 3 in immune cell function and tumorigenesis has important clinical significance.

As a drug target, DP alpha 3 may be used to treat many immune-related diseases. For example, by regulating the function of DP alpha 3, immune cell function can be improved and the anti-tumor ability of the immune system can be enhanced, thereby treating tumors. In addition, DP alpha 3 can also be used as a tumor biomarker for early diagnosis of tumors and evaluation of treatment effects.

Currently, research on DP alpha 3 mainly focuses on molecular biology and biochemistry. For example, researchers are studying the relationship between mutations in the gene encoding DP alpha 3 and immune cell function, and how DP alpha 3 participates in the molecular mechanisms of immune cell differentiation and tumorigenesis. In addition, the researchers also studied the role of DP alpha 3 in immune cell responses and how DP alpha 3 regulates immune cell activation and proliferation.

DP alpha 3, as an important immune cell molecule, plays an important role in the function of the immune system. By studying the molecular biology and biochemical properties of DP alpha 3, we can provide important theoretical and experimental foundations for the development of new immunomodulatory drugs. At the same time, DP alpha 3 may also become an important biomarker for studying the occurrence and development of tumors, providing an important theoretical basis for the early diagnosis and treatment of tumors.

Protein Name: Major Histocompatibility Complex, Class II, DP Alpha 3 (pseudogene)

The "HLA-DPA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA-DPA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets